FAZA PETMRI Kidney Graft Fibrosis Study
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Nov 25, 2022
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years
- • 2. Evidence of impaired kidney graft function based on elevated serum creatinine from baseline and/ or evidence of significant proteinuria and/or donor specific antibodies
- • 3. A negative urine or serum pregnancy test within the three week interval immediately prior to imaging, in women of child-bearing age
- • 4. Ability to provide written informed consent to participate in the study (for both patients groups - with and without impaired kidney graft function)
- 5. Two study groups:
- • Evidence of impaired kidney graft function based on elevated serum creatinine from baseline and/ or evidence of significant proteinuria and/or donor specific antibodies and scheduled for a kidney graft biopsy.
- • comparison (control) group with stable kidney graft function, matched for graft/recipient age, sex and comorbidities
- Exclusion Criteria:
- • 1. Contraindication for MR as per current institutional guidelines
- • 2. Inability to lie supine for at least 30 minutes
- • 3. Any patient who is pregnant or breastfeeding
- • 4. Any patient unable or unwilling to provide informed consent
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Patrick Veit-Haibach, MD
Principal Investigator
University Health Network, Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials